| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
HDAC5 phosphorylation and angiotensin II-induced neonatal cardiomyocyte hypertrophy are both markedly inhibited by KR-39038 (0-1.0 μM, 24 hours) [1].
|
|---|---|
| ln Vivo |
KR-39038 (0-30 mg/kg, orally, once daily for 14 days) substantially lowers ventricular hypertrophy and dysfunction in experimental heart failure [1]. Pharmacokinetic characteristics of KR-39038 in Sprague-Dawley rats [1]. Parameter IV (5 mg/kg) PO (300 mg/kg) Cmax (μg/mL) NA 5.2 ± 2.8 Tmax (h) NA 0.7 ± 0.2 t1/2 (h) 0.7 ± 0.04 2.3 ± 2.9 AUC0-∞ (μg ) *h/mL) 3.4 ± 1.0 8.9 ± 5.0 CL (L/h/kg) 1.6 ± 0.5 NA Vss (L/kg) 1.2 ± 0.2 NA F (%) 4.3 ± 2.4
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Primary neonatal cardiomyocytes (isolated from SD rats (1-2 days old) using primary cardiomyocyte isolation kit) Tested Concentrations: 0 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM Incubation Duration: 24 hrs (hours) Experimental Results: Cell hypertrophy induced by angiotensin II was Dramatically inhibited at concentrations of 0.1 μM and higher. Angiotensin II-induced HDAC5 phosphorylation is diminished at 0.3 µM and higher. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice ( Male, 20-24 g, transverse aortic coarctation) [1]
Doses: 30 mg/kg Route of Administration: Orally, one time/day for 2 weeks, starting 24 hrs (hrs (hours)) after surgery Experimental Results: 43% reduction in left ventricular weight, and Dramatically attenuated the development of cardiac hypertrophy. Animal/Disease Models: SD (SD (Sprague-Dawley)) rat (male, 380-420 g, coronary artery ligation) [1] Doses: 10 mg/kg, 30 mg/kg Route of Administration: Orally, one time/day for 12 weeks, Results one hour after surgery starting on the 24th: demonstrated significant preservation of cardiac function and attenuation of myocardial remodeling in a rat model of chronic heart failure after coronary artery ligation. Animal/Disease Models: SD rat[1] Doses: 5 mg/kg (intravenous (iv) (iv)injection), 300 mg/kg (oral) Route of Administration: intravenous (iv) (iv)injection or oral administration, single dose (pharmacokinetic/PK/PK analysis) Experimental Results: After intravenous (iv) (iv)injection The AUC∞ values of KR-39038 at 10 mg/kg and 300 mg/kg orally were 3.4 ± 1.0 and 8.9 ± 5.0 µg·h/mL, |
| References |
| Molecular Formula |
C24H32CLFN6O
|
|---|---|
| Molecular Weight |
475.001887321472
|
| Exact Mass |
474.231
|
| CAS # |
2770300-35-9
|
| PubChem CID |
163404364
|
| Appearance |
White to yellow solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
33
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1C2=C(C=C(F)C(NCCCNCCCCNCCCN)=C2)C(=O)NC=1C1=CC=CC=C1Cl
|
| InChi Key |
UEAYNKFJXGVWBQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H32ClFN6O/c25-19-8-2-1-7-17(19)23-31-21-16-22(20(26)15-18(21)24(33)32-23)30-14-6-13-29-11-4-3-10-28-12-5-9-27/h1-2,7-8,15-16,28-30H,3-6,9-14,27H2,(H,31,32,33)
|
| Chemical Name |
7-[3-[4-(3-aminopropylamino)butylamino]propylamino]-2-(2-chlorophenyl)-6-fluoro-3H-quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~115 mg/mL (~242.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1053 mL | 10.5263 mL | 21.0526 mL | |
| 5 mM | 0.4211 mL | 2.1053 mL | 4.2105 mL | |
| 10 mM | 0.2105 mL | 1.0526 mL | 2.1053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
